# Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis

> **NCT05045248** · PHASE2 · COMPLETED · sponsor: **American University of Beirut Medical Center** · enrollment: 10 (actual)

## Conditions studied

- Myasthenia Gravis
- Ocular Myasthenia Gravis

## Interventions

- **DRUG:** Apraclonidine Hcl 0.5% Oph Soln

## Key facts

- **NCT ID:** NCT05045248
- **Lead sponsor:** American University of Beirut Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-01
- **Primary completion:** 2021-04-15
- **Final completion:** 2021-04-15
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2021-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05045248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05045248, "Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05045248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*